Cargando…
New targets for therapy in breast cancer: Farnesyltransferase inhibitors
Current systemic therapies for breast cancer are often limited by their nonspecific mechanism of action, unwanted toxicities on normal tissues, and short-term efficacy due to the emergence of drug resistance. However, identification of the molecular abnormalities in cancer, in particular the key pro...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2004
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064090/ https://www.ncbi.nlm.nih.gov/pubmed/15535857 http://dx.doi.org/10.1186/bcr947 |